First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.

被引：1
|
作者：
Beslija, S. [1 ]
Brodowicz, T. [1 ]
Greil, R. [1 ]
Inbar, M. J. [1 ]
Kahan, Z. [1 ]
Kaufman, B. [1 ]
Lang, I. [1 ]
Steger, G. G. [1 ]
Stemmer, S. M. [1 ]
Zielinski, C. [1 ]
Zvirbule, Z. [1 ]
机构：
[1] CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/000B-5472.SABCS11-OT2-01-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-02
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience
    Lorenzo Livi
    Pierluigi Bonomo
    Icro Meattini
    Gabriele Simontacchi
    Daniela Greto
    Isacco Desideri
    Fiammetta Meacci
    Vieri Scotti
    Sara Cecchini
    Jacopo Nori
    Luis Jose Sanchez
    Lorenzo Orzalesi
    Fabiola Paiar
    Gianpaolo Biti
    Medical Oncology, 2013, 30
  • [32] Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience
    Livi, Lorenzo
    Bonomo, Pierluigi
    Meattini, Icro
    Simontacchi, Gabriele
    Greto, Daniela
    Desideri, Isacco
    Meacci, Fiammetta
    Scotti, Vieri
    Cecchini, Sara
    Nori, Jacopo
    Sanchez, Luis Jose
    Orzalesi, Lorenzo
    Paiar, Fabiola
    Biti, Gianpaolo
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [33] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    Altundag, Kadri
    TUMORI JOURNAL, 2015, 101 (04): : 418 - 423
  • [34] A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC).
    Mavroudis, D.
    Boukovinas, I.
    Christophyllakis, C.
    Xenidis, N.
    Papakotoulas, P.
    Malamos, N. A.
    Kakolyris, S.
    Polyzos, A.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Weekly paclitaxel and capecitabine in HER2-negative metastatic breast cancer (MBC): A multicenter GINECO randomized phase II comparing two paclitaxel-capecitabine schedules
    Lortholary, A.
    Hardy-Bessard, A. C.
    Bachelot, T.
    Dalivoust, P.
    de Rauglaudre, G.
    Alexandre, J.
    Bourgeois, H.
    Jaubert, D.
    Paraiso, D.
    Largillier, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
    Lam, Siu W.
    de Groot, Steffen M.
    Honkoop, Aafke H.
    Nota, Nienke M.
    Jager, A.
    van der Velden, Ankle M. T.
    Bos, Monique M. E. M.
    Linn, Sabine C.
    Van Den Bosch, J.
    Kroep, Judith R.
    Braun, J. J.
    de Haas, Richard R.
    Smorenburg, Carolien H.
    de Graaf, Hiltje
    Portielje, Johanna Elisabeth A.
    Los, Maartje
    de Gooyer, Domingo
    van Tinteren, Harm
    Boven, Epie
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
    Musolino, A.
    Bisagni, G.
    De Matteis, A.
    Nuzzo, F.
    Ardizzoni, A.
    Crino, L.
    Gamucci, T.
    Passalacqua, R.
    Gnoni, R.
    Boni, C.
    CANCER RESEARCH, 2010, 70
  • [38] Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
    Delaloge, S.
    Perol, D.
    Courtinard, C.
    Brain, E.
    Asselain, B.
    Bachelot, T.
    Debled, M.
    Dieras, V.
    Campone, M.
    Levy, C.
    Jacot, W.
    Lorgis, V.
    Veyret, C.
    Dalenc, F.
    Ferrero, J. M.
    Uwer, L.
    Kerbrat, P.
    Goncalves, A.
    Mouret-Reynier, M. A.
    Petit, T.
    Jouannaud, C.
    Vanlemmens, L.
    Chenuc, G.
    Guesmia, T.
    Robain, M.
    Cailliot, C.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1725 - 1732
  • [39] Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
    Dieras, V.
    Glaspy, J.
    Brufsky, A.
    Bondarenko, I.
    Lipatov, O.
    Perez, E. A.
    Chan, S.
    Zhou, X.
    Phan, S. C.
    Robert, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 265 - 265
  • [40] A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine manotherapy in first-line HER2-negative metastatic breast cancer (MBC).
    Goldstein, Lori J.
    Oliveira, Celia Tosello
    Heinrich, Bernhard
    Stemmer, Salomon M.
    Mala, Carola
    Kastner, Sabine
    Bevan, Paul
    Richters, Lisa
    Schmalfeldt, Barbara
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345